BioNTech's Founders Sell Shares and Face Fresh Patent Suits as German Plants Wind Down

Moderna filed a patent claim against BioNTech at the Unified Patent Court as BioNTech plans to shut three German sites affecting 1,800 staff.

BioNTech is navigating a thicket of legal challenges and a sweeping manufacturing retreat at the same time that its founding couple prepares to step away from the company they built into a pandemic-era powerhouse.

On the legal front, U.S. rival Moderna has taken its patent fight to the Unified Patent Court, filing a claim with the Hamburg local division on Friday. The suit alleges infringement of patent EP 3 981 437, which covers nucleic acid vaccines. Moderna is seeking damages tied to vaccine revenues earned since the start of the pandemic, though reports indicate it is not asking for a sales ban on BioNTech's products. The case marks the Hamburg chamber's first major mRNA dispute, and it lands after Moderna suffered setbacks in Europe: the European Patent Office's boards of appeal revoked its EP 3 590 949 patent in mid-September, following an earlier invalidation of another right in January.

That is not the only courtroom pressure. On September 28, a federal judge in Delaware declined a request from BioNTech and partner Pfizer to dismiss a Bayer patent suit concerning mRNA technology, with Reuters reporting a comparable ruling against Moderna. The decision is an interim step rather than a final judgment, but it opens the door to protracted litigation over licensing and intellectual property rights.

Production Pullback Hits Three German Sites

The legal wrangling coincides with painful cuts on home soil. Unable to find buyers for certain production facilities, BioNTech announced on September 28 that it will gradually shut down its Marburg, Tübingen and Idar-Oberstein locations, affecting roughly 1,800 employees. Under the timeline, Tübingen closes by the end of 2027, Marburg in early 2028 and Idar-Oberstein by the end of 2028. The moves have stirred sharp criticism locally: the works council in Idar-Oberstein described a serious breach of trust, while Tübingen's mayor, Boris Palmer, condemned the closure of the former CureVac site and warned about the loss of skilled workers and German RNA production capacity.

Insider Sales Follow a Pre-Set Schedule

Against that backdrop, CEO U?ur ?ahin has been trimming his stake. SEC filings show he sold 34,000 ordinary shares on September 29 and another 32,000 the following day, transactions carried out under a trading plan established on June 3, 2026, in line with Rule 10b5-1. Such arrangements automate sales independently of short-term market moves or internal events. The disposals add to a series of September sales by the co-founder, including 17,000 shares sold on Thursday at an average price of USD 97.46 apiece, a volume of roughly USD 1.66 million.

Investors are also watching a broader leadership transition: ?ahin and medical chief Özlem Türeci intend to leave BioNTech by the end of 2026 to launch a new venture focused on early-stage mRNA drug research. BioNTech is in talks over a minority stake as well as the contribution of technology and licensing rights.

The Oncology Bet Takes Center Stage

What ultimately drives the valuation is whether BioNTech can pull off a profitable shift from Covid-19 pioneer to established oncology player. Revenue from the original vaccine business has fallen sharply since the pandemic, while clinical development of new candidates consumes substantial capital. Shareholders want hard evidence that the company's messenger RNA technology can deliver clinical breakthroughs in cancer therapy as well.

Optimists point to recent pipeline progress. About two weeks ago, updated Phase 3 data for oncology candidate Gotistobart showed a doubling of survival time, lifting the stock 2.9 percent since. Health Canada's approval of an updated Covid-19 vaccine around the same period underscores the continued relevance of the existing core business. Analyst support has followed: Berenberg raised its price target for BioNTech roughly two weeks ago, and the shares have gained 3.0 percent since. Year to date, the stock is up 5.8 percent in a demanding sector environment.

What Traders Are Watching

The shares ended Friday at EUR 86.10, giving the Mainz-based group a market value of EUR 21.59 billion. Technically, the recovery trend holds as long as the price defends its 200-day moving average of EUR 84.58; a sustained break below that line would risk a retest of lower support zones.

For now, investors must weigh whether the staffing and infrastructure cuts will unlock the financial flexibility management is counting on, or whether legal uncertainty and operational friction will overshadow progress. Upcoming clinical study readouts and further developments in the U.S. patent disputes are the next key catalysts, with market participants tracking how quickly BioNTech executes its closure plans and what interim data its oncology pipeline can deliver at the coming conference rounds.